210 related articles for article (PubMed ID: 30124992)
21. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
22. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
Marcos-Zambrano LJ; Gómez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
Clin Microbiol Infect; 2018 Dec; 24(12):1343.e1-1343.e4. PubMed ID: 30025834
[TBL] [Abstract][Full Text] [Related]
23.
Raffetin A; Courbin V; Jullien V; Dannaoui E
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038263
[No Abstract] [Full Text] [Related]
24.
Broutin A; Bigot J; Senghor Y; Moreno-Sabater A; Guitard J; Hennequin C
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767726
[TBL] [Abstract][Full Text] [Related]
25. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.
Verweij PE; González GM; Wiedrhold NP; Lass-Flörl C; Warn P; Heep M; Ghannoum MA; Guinea J
J Chemother; 2009 Jun; 21(3):272-81. PubMed ID: 19567347
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.
Chryssanthou E; Cuenca-Estrella M
Clin Microbiol Infect; 2006 Sep; 12(9):901-4. PubMed ID: 16882296
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Perkhofer S; Lechner V; Lass-Flörl C;
Antimicrob Agents Chemother; 2009 Apr; 53(4):1645-7. PubMed ID: 19164153
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of isavuconazole against clinically isolated yeasts from Chile.
Álvarez Duarte E; Salas V
Braz J Microbiol; 2020 Dec; 51(4):1801-1805. PubMed ID: 32638272
[TBL] [Abstract][Full Text] [Related]
31. In vitro synergy of isavuconazole in combination with colistin against Candida auris.
Schwarz P; Bidaud AL; Dannaoui E
Sci Rep; 2020 Dec; 10(1):21448. PubMed ID: 33293607
[TBL] [Abstract][Full Text] [Related]
32. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.
Datta K; Rhee P; Byrnes E; Garcia-Effron G; Perlin DS; Staab JF; Marr KA
J Clin Microbiol; 2013 Sep; 51(9):3090-3. PubMed ID: 23804388
[TBL] [Abstract][Full Text] [Related]
33. Colistin and Isavuconazole Interact Synergistically In Vitro against
Schwarz P; Djenontin E; Dannaoui E
Microorganisms; 2020 Sep; 8(9):. PubMed ID: 32967270
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
[TBL] [Abstract][Full Text] [Related]
35. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
Serrano MC; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Ramírez M; Mazuelos EM
J Clin Microbiol; 2003 Nov; 41(11):5270-2. PubMed ID: 14605181
[TBL] [Abstract][Full Text] [Related]
37. Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus.
Meletiadis J; Leth Mortensen K; Verweij PE; Mouton JW; Arendrup MC
Clin Microbiol Infect; 2017 Feb; 23(2):98-103. PubMed ID: 27793736
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.
Chowdhary A; Singh PK; Kathuria S; Hagen F; Meis JF
Antimicrob Agents Chemother; 2015 Dec; 59(12):7882-7. PubMed ID: 26438489
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of isavuconazole against clinically relevant Trichosporon species: a comparative evaluation of EUCAST broth microdilution and MIC Test Strip methods.
Francisco EC; Dieleman C; Hagen F; Colombo AL;
J Antimicrob Chemother; 2023 Mar; 78(3):817-822. PubMed ID: 36702754
[TBL] [Abstract][Full Text] [Related]
40. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.
Katragkou A; McCarthy M; Meletiadis J; Petraitis V; Moradi PW; Strauss GE; Fouant MM; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2014 Nov; 58(11):6934-7. PubMed ID: 25136021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
